首页> 外文OA文献 >Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

【2h】

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

机译：Navitoclax，Bcl-2的靶向高亲和力抑制剂，淋巴恶恶性肿瘤：安全，药代动力学，药效学和抗肿瘤活性的1阶段剂量升级研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Wyndham H Wilson; Owen A OConnor; Myron S Czuczman; Ann S LaCasce; John F Gerecitano; John P Leonard; Anil Tulpule; Kieron Dunleavy; Hao Xiong; Yi-Lin Chiu; Yue Cui; Todd Busman; Steven W Elmore; Saul H Rosenberg; Andrew P Krivoshik; Sari H Enschede; Rod A Humerickhouse;
展开▼
作者单位

展开▼
年度 2010
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. [J] . Wilson WH, OConnor OA, Czuczman MS, The lancet oncology . 2010,第12期

机译：Navitoclax是BCL-2的靶向高亲和力抑制剂，可用于淋巴恶性肿瘤：安全性，药代动力学，药效学和抗肿瘤活性的1期剂量递增研究。
2. Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20(+) lymphoid malignancies [J] . Roberts Andrew W., Advani Ranjana H., Kahl Brad S., British Journal of Haematology . 2015,第5期

机译：BCL2抑制剂navitoclax联合利妥昔单抗治疗复发或难治性CD20（+）淋巴恶性肿瘤患者的安全性，药代动力学和抗肿瘤活性的1期研究
3. Preliminary Safety, Pharmacokinetic, and Pharmacodynamic Results from a Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of the Noncovalent, Reversible Bruton's Tyrosine Kinase Inhibitor (BTKi), Vecabrutinib, in B-Lymphoid Malignancies [J] . Allan John N., Wierda William G., Patel Krish, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：初步安全性，药代动力学和药效学结果由非共价，可逆的Bruton的酪氨酸激酶抑制剂（BTKI），Vecabrutinib，在B淋巴恶恶性肿瘤中的1B / 2剂量 - 升级和群组 - 膨胀研究
4. Pharmacokinetics, pharmacodynamics, metabolism, transport, and resistance studies of a novel histone deacetylase inhibitor FK228 (FR901228, NSC630176). [D] . Xiao, Jin. 2004

机译：新型组蛋白脱乙酰基酶抑制剂FK228（FR901228，NSC630176）的药代动力学，药效学，代谢，转运和抗药性研究。
5. Safety Pharmacokinetics Pharmacodynamics and Activity of Navitoclax a Targeted High Affinity Inhibitor of BCL-2 in Lymphoid Malignancies [O] . Wyndham H. Wilson, Owen A. O’Connor, Myron S. Czuczman, -1

机译：安全性药代动力学药效学和Navitoclax的活性靶向BCL-2的高亲和力抑制剂在淋巴样恶性肿瘤
6. Safety and efficacy of navitoclax, a BCL-2 and BCL-XL inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study [O] . Sven de Vos, John P. Leonard, Jonathan W. Friedberg, 2020

机译：Navitoclax，Bcl-2和Bcl-XL抑制剂的安全性和有效性，复发或难治性淋巴恶恶性肿瘤的患者：2A研究结果

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

著录项

相似文献

相关主题

期刊订阅